Cargando…
Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
INTRODUCTION: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women. The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV). MATERIAL AN...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901026/ https://www.ncbi.nlm.nih.gov/pubmed/24386936 http://dx.doi.org/10.1186/1878-5085-5-1 |
_version_ | 1782300791255597056 |
---|---|
author | Lazarenko, Liudmyla M Nikitina, Olena E Nikitin, Evgen V Demchenko, Olga M Kovtonyuk, Galyna V Ganova, Larysa O Bubnov, Rostyslav V Shevchuk, Veronika O Nastradina, Natalia M Bila, Viktoria V Spivak, Mykola Ya |
author_facet | Lazarenko, Liudmyla M Nikitina, Olena E Nikitin, Evgen V Demchenko, Olga M Kovtonyuk, Galyna V Ganova, Larysa O Bubnov, Rostyslav V Shevchuk, Veronika O Nastradina, Natalia M Bila, Viktoria V Spivak, Mykola Ya |
author_sort | Lazarenko, Liudmyla M |
collection | PubMed |
description | INTRODUCTION: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women. The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV). MATERIAL AND METHODS: The study involved 71 women with cervical precancerous diseases (mean age 26 ± 5 years) revealed by colposcopic, cytomorphological, and ultrasound signs which were assessed according to the following: first group, 44 patients infected with HPV; second group, 27 HPV-negative patients; and third group, 30 healthy patients (controls). In cervical specimen, we identified HPV DNA of different oncogenic risk types by polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) kits (JSC SPC ‘DiaprofMed’) were used for detecting antibodies to HSV1 and/or HSV2 and for determining the avidity index. The production of pro-inflammatory cytokines, interferon-γ (IFN-γ), IFN-α, TNF-α, and interleukin-1β (IL-1β), and anti-inflammatory cytokines, IL-4, IL-10, and transforming growth factor-β1 (TGF-β1), were studied by ELISA. RESULTS: In HPV-induced cervix precancerous diseases, we identified low-avidity IgG antibodies to HSV serum of 20 patients; in the serum of 17 patients, we identified average-avidity antibodies, and high-avidity antibodies were found in 2 patients only. In 14 HPV-negative patients, we found low-avidity IgG antibodies to HSV; in 10 patients, medium avidity. Patients with low-avidity IgG antibodies to herpes virus showed high and medium oncogenic risk HPV types and a decrease of IFN-γ compared to patients with medium-avidity IgG antibodies. Production of IFN-γ was suppressed also in HPV-negative patients with cervical precancers, but we found low- and medium-avidity IgG antibodies to herpes virus. In patients with low-avidity antibodies, we observed increased level of IL-10. Level of IFN-α, IL-1β, IL-2, and IL-4 did not change in patients of all groups, but TGF-β1 increased. CONCLUSIONS: In HPV-positive patients, those with low-avidity IgG antibodies to HSV had immunosuppression, confirmed by increased TGF-β1 and violation of IFN-γ production. Therefore, in pro- and anti-inflammatory cytokines and IgG antibodies to HSV, their avidity is an important diagnostic biomarker of HPV-induced precancerous cervical diseases. Low-avidity IgG antibodies may be an indication for treatment with immunomodulators and antiviral drugs. |
format | Online Article Text |
id | pubmed-3901026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39010262014-01-25 Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions Lazarenko, Liudmyla M Nikitina, Olena E Nikitin, Evgen V Demchenko, Olga M Kovtonyuk, Galyna V Ganova, Larysa O Bubnov, Rostyslav V Shevchuk, Veronika O Nastradina, Natalia M Bila, Viktoria V Spivak, Mykola Ya EPMA J Research INTRODUCTION: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women. The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV). MATERIAL AND METHODS: The study involved 71 women with cervical precancerous diseases (mean age 26 ± 5 years) revealed by colposcopic, cytomorphological, and ultrasound signs which were assessed according to the following: first group, 44 patients infected with HPV; second group, 27 HPV-negative patients; and third group, 30 healthy patients (controls). In cervical specimen, we identified HPV DNA of different oncogenic risk types by polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) kits (JSC SPC ‘DiaprofMed’) were used for detecting antibodies to HSV1 and/or HSV2 and for determining the avidity index. The production of pro-inflammatory cytokines, interferon-γ (IFN-γ), IFN-α, TNF-α, and interleukin-1β (IL-1β), and anti-inflammatory cytokines, IL-4, IL-10, and transforming growth factor-β1 (TGF-β1), were studied by ELISA. RESULTS: In HPV-induced cervix precancerous diseases, we identified low-avidity IgG antibodies to HSV serum of 20 patients; in the serum of 17 patients, we identified average-avidity antibodies, and high-avidity antibodies were found in 2 patients only. In 14 HPV-negative patients, we found low-avidity IgG antibodies to HSV; in 10 patients, medium avidity. Patients with low-avidity IgG antibodies to herpes virus showed high and medium oncogenic risk HPV types and a decrease of IFN-γ compared to patients with medium-avidity IgG antibodies. Production of IFN-γ was suppressed also in HPV-negative patients with cervical precancers, but we found low- and medium-avidity IgG antibodies to herpes virus. In patients with low-avidity antibodies, we observed increased level of IL-10. Level of IFN-α, IL-1β, IL-2, and IL-4 did not change in patients of all groups, but TGF-β1 increased. CONCLUSIONS: In HPV-positive patients, those with low-avidity IgG antibodies to HSV had immunosuppression, confirmed by increased TGF-β1 and violation of IFN-γ production. Therefore, in pro- and anti-inflammatory cytokines and IgG antibodies to HSV, their avidity is an important diagnostic biomarker of HPV-induced precancerous cervical diseases. Low-avidity IgG antibodies may be an indication for treatment with immunomodulators and antiviral drugs. BioMed Central 2014-01-06 /pmc/articles/PMC3901026/ /pubmed/24386936 http://dx.doi.org/10.1186/1878-5085-5-1 Text en Copyright © 2014 Lazarenko et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lazarenko, Liudmyla M Nikitina, Olena E Nikitin, Evgen V Demchenko, Olga M Kovtonyuk, Galyna V Ganova, Larysa O Bubnov, Rostyslav V Shevchuk, Veronika O Nastradina, Natalia M Bila, Viktoria V Spivak, Mykola Ya Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
title | Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
title_full | Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
title_fullStr | Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
title_full_unstemmed | Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
title_short | Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
title_sort | development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901026/ https://www.ncbi.nlm.nih.gov/pubmed/24386936 http://dx.doi.org/10.1186/1878-5085-5-1 |
work_keys_str_mv | AT lazarenkoliudmylam developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT nikitinaolenae developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT nikitinevgenv developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT demchenkoolgam developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT kovtonyukgalynav developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT ganovalarysao developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT bubnovrostyslavv developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT shevchukveronikao developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT nastradinanataliam developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT bilaviktoriav developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions AT spivakmykolaya developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions |